The efficacy and safety of semaglutide have been established in the SUSTAIN clinical trial programme across the continuum of care in patients with type 2 diabetes
The SUSTAIN clinical development programme for once-weekly subcutaneous semaglutide injection currently comprises 11 phase 3 global clinical trials
The SUSTAIN program of randomized control trials (RCT) established the efficacy and safety of semaglutide, showing superior and clinically significant glycemic
3–8 In SUSTAIN 6, semaglutide demon-strated a significant 26% risk reduction for the primary composite CV outcome vs placebo at 2 years
This webinar will support your work in High Fidelity Wraparound Implementation
of semaglutide in the SUSTAIN programme was consistent with that of the GLP-1 receptor agonist class
3 million in funding from its Transportation Enhancement Grants program for transportation safety
8 Microvascular complications were evaluated as a secondary endpoint; a significantly lower risk of new or worsening nephropathy was reported with semaglutide vs placebo Patients in the SURE UK study also experienced HbA 1c and weight reductions that are consistent with those observed in the phase 3 RCTs in the SUSTAIN programme, where change in HbA 1c ranged from − 1
Rybelsus‚ also known by its generic name semaglutide‚ is an innovative oral medication used for the management of type 2 diabetes
versus that of once-weekly exenatide ER 2
We would like to show you a description here but the site won’t allow us
In SUSTAIN 6, a 2-year, pre-approval cardiovascular outcomes trial, semaglutide was associated with a significant increase in the risk of DR complications The efficacy and safety of OW subcutaneous (s
1
The phase 3 SUSTAIN clinical trial programme explored the efficacy and safety of once-weekly (OW) semaglutide in a broad range of subjects with T2D [10,11,12,13,14,15,16,17,18]
c
SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a global phase III clinical trial programme, designed to evaluate the efficacy and safety of once-weekly s
0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk
In SUSTAIN 6, a 2-year, pre-approval cardiovascular outcomes trial, semaglutide was associated with a significant increase in the risk of DR complications (DRC) vs placebo
semaglutide provided good glycaemic control versus a wide range of
DR AEs in SUSTAIN 5 are discussed in a publication that analyzes DR in the SUSTAIN clinical program